Calcilytix Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Calcilytix Therapeutics's estimated annual revenue is currently $2.3M per year.
- Calcilytix Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Calcilytix Therapeutics has 15 Employees.
- Calcilytix Therapeutics grew their employee count by 15% last year.
Calcilytix Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director | Reveal Email/Phone |
2 | Associate Director - Drug Substance Development and Manfacturing | Reveal Email/Phone |
3 | Director, Analytical Development | Reveal Email/Phone |
4 | Senior Clinical Trial Manager | Reveal Email/Phone |
Calcilytix Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Calcilytix Therapeutics?
Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 15 | 0% | N/A |
#2 | $2.3M | 15 | -21% | N/A |
#3 | $0.4M | 15 | -42% | $156.1M |
#4 | $0.7M | 15 | -29% | $96.4M |
#5 | $1.2M | 15 | N/A | N/A |